The European Hector Research Award in HIV 2021 awarded to Angela Colbers and David Burger2 November 2021
On Friday 29 October 2021, during the 18th European AIDS Conference in London, the Hector Research Award for the best scientific article related to clinical or epidemiological HIV research was presented to Angela Colbers and David Burger, both working in the Pharmacy of the RadboudUMC.
Rob Aarnoutse is appointed as professor in Translation pharmacology of antimicrobial agents in particular drugs for tuberculosis25 January 2021
Hospital pharmacist and clinical pharmacologist Rob Aarnoutse is appointed as professor in ‘Translation pharmacology of antimicrobial agents, in particular drugs for tuberculosis’ at Radboud University / Radboudumc, starting 16 November 2020.
The patient's need for medication information and its perceived quality3 September 2020
In the International Journal of Clinical Pharmacy Charlotte Bekker showed that patients often face unmet medication information needs and that the quality of the provided information, including accessibility, comprehensiveness, reliability and understandability, is perceived as insufficient.
Radboudumc research leads to simplified dose of HIV medication for children31 August 2020
For children living with HIV, an adapted, simpler combination therapy is now available. Thanks to research by the Radboudumc, it is now clear that the use of one easily available tablet of dolutegravir in children gives just as good treatment results as a combination of several.
650,000 Euro funding for research into the phasing out of medication for leukaemia patients30 July 2020
With a 650,000 euro funding from ZonMw, researchers from the Haematology and Pharmacy departments can develop a medication phasing out strategy for patients with chronic myeloid leukaemia. This strategy will be tested in practice.
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2)12 May 2020
In Lancet HIV RIHS researchers Angela Colbers and David Burger showed in an open-label, randomized controlled trial, that, when initiated in the 3rd trimester of pregnancy, achievement of VL <50cp/mL at delivery was more likely with dolutegravir-based therapy than with efavirenz-based regimens.
The effect of pregnancy on the pharmacokinetics of dolutegravir in women living with HIV17 March 2020
In Clinical infectious diseases RIHS researchers Pauline Bollen, Jolien Freriksen, Angela Colbers and David Burger together with researchers of the PANNA network showed that dolutegravir use in pregnancy results in effective plasma concentrations.
Dosing anticancer drugs in patients with renal or hepatic impairment11 April 2019
Renal or hepatic impairment is a common comorbidity for patients with cancer either because of the disease itself, toxicity of previous anticancer treatments, or because of other factors affecting organ function, such as increased age.
Importance of prospective studies in pregnant and breastfeeding women living with HIV14 March 2019
In Clinical Infectious Diseases Angela Colbers, Stein Schalkwijk and David Burger give considerations on how to effectively evaluate aspects of clinical pharmacology required for safe and effective treatment to optimize pharmacotherapy during pregnancy and breastfeeding.
Pharmacy receives prestigious European prize for research in Africa27 September 2018
On 17 September, David Burger, professor of clinical pharmacy, together with colleagues from the United Kingdom, Uganda and Zimbabwe, received the "Outstanding Research Team" award from the European - Developing Countries Clinical Trial Partnership (EDCTP).
WHO Toolkit Pregnant and breastfeeding women8 August 2018
Stein Schalkwijk, Angela Colbers and David Burger (Pharmacy) developed the Toolkit in cooperation with Mark Mirochnick (Boston University) as a part of “Toolkit for research and development of paediatric antiretroviral drugs and formulations”.
Pharmacokinetics of HIV medicines in pregnant women28 June 2018
In Clinical Pharmacokinetics David Burger, Ruben van der Galiën and colleagues discuss that although yearly over a million of women with HIV get pregnant, it is often still unknown whether treatment with HIV-integrase inhibitors results in adequate drug exposure.